BRPI0713402A2 - use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma - Google Patents
use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma Download PDFInfo
- Publication number
- BRPI0713402A2 BRPI0713402A2 BRPI0713402-9A BRPI0713402A BRPI0713402A2 BR PI0713402 A2 BRPI0713402 A2 BR PI0713402A2 BR PI0713402 A BRPI0713402 A BR PI0713402A BR PI0713402 A2 BRPI0713402 A2 BR PI0713402A2
- Authority
- BR
- Brazil
- Prior art keywords
- melanoma
- prepare
- stage
- treatment
- drug
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 102000007501 Thymosin Human genes 0.000 title abstract 2
- 108010046075 Thymosin Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 229950000038 interferon alfa Drugs 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DA TIMOSINA ALFA 1 PARA PREPARAR UM MEDICAMENTO PARA O TRATAMENTO DO MELANOMA MALIGNO EM ESTáGIO IV. A presente invenção refere-se ao uso da timosina alfa em combinação com a dacarbazina e opcionalmente com Interferona alfa para preparar um medicamento para o tratamento do melanoma maligno no estágio IV, caracterizado por metástase distante não-operável.USE OF ALPHA 1 TIMOSINE TO PREPARE A MEDICINAL PRODUCT FOR TREATMENT OF MALIGNO MELANOMA IN STAGE IV. The present invention relates to the use of thymosin alfa in combination with dacarbazine and optionally interferon alfa to prepare a medicament for the treatment of stage IV malignant melanoma characterized by distant non-operable metastasis.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/424,425 | 2006-06-15 | ||
| US11/424,425 US7481633B2 (en) | 2006-06-15 | 2006-06-15 | Rotor with cut-outs |
| US11/734,592 US8017129B2 (en) | 2006-06-15 | 2007-04-12 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| US11/734,592 | 2007-04-12 | ||
| PCT/EP2007/053712 WO2007144218A1 (en) | 2006-06-15 | 2007-04-17 | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0713402A2 true BRPI0713402A2 (en) | 2012-03-13 |
Family
ID=45809859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0713402-9A BRPI0713402A2 (en) | 2006-06-15 | 2007-04-17 | use of thymosin alfa 1 to prepare a drug for the treatment of stage iv melanoma melanoma |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BRPI0713402A2 (en) |
-
2007
- 2007-04-17 BR BRPI0713402-9A patent/BRPI0713402A2/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201903693T4 (en) | dosing and drive mechanism for the drug delivery device. | |
| PL1986669T3 (en) | The use of Bifidobacterium longum for the prevention and treatment of inflammation | |
| CL2012003026A1 (en) | Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity. | |
| GEP20135902B (en) | Injection syringe for therapeutic agent | |
| UA105210C2 (en) | Anti-cancer vaccine and use thereof | |
| BRPI0719009B8 (en) | dosing and triggering mechanism for drug delivery devices | |
| ATE493161T1 (en) | MEDICAL DELIVERY SYSTEM WITH ASYMMETRIC CODING DEVICES | |
| IL185808A0 (en) | Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments | |
| UY27720A1 (en) | MONOCYCLIC AROILPIRIDINONES, | |
| EA200802247A1 (en) | DOSING SCHEME OF KLADRIBIN FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| MY173629A (en) | Dosage form | |
| NZ588913A (en) | Liver cancer drug | |
| BRPI0717369A2 (en) | COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND. | |
| DE60327693D1 (en) | TOPICAL COMPOSITION CONTAINING A CYCLOFRUCTAN, A CARRIER AND A MEDICAMENT | |
| TW200800954A (en) | Novel crystal modifications | |
| CL2011002962A1 (en) | Use of at least one specific integrin ligand for the treatment of cancer, and where the drug is to be used in combination with at least one additional agent selected from a) one or more alkylating agents and b) one or more chemotherapeutic agents other than those previous. | |
| CL2009000665A1 (en) | Pyrrolidinyl derived compounds; pharmaceutical composition comprising said compounds; and its use in the treatment of anxiety, depression or both. | |
| CL2009001841A1 (en) | Use of a sustained release composition of 4-aminopyridine to prepare a medicament useful for treating multiple sclerosis in a subject. | |
| CO6361943A2 (en) | CYCLOUNDECADEPSIPEPTIDE COMPOUNDS AND THE USE OF SUCH COMPOUNDS AS A MEDICINAL PRODUCT | |
| SG160415A1 (en) | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | |
| AR061352A1 (en) | THE USE OF TIMOSINA ALFA 1 TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF MALIGNOM MELANOMA OF STADIUM IV | |
| NO20091628L (en) | combination Drug | |
| TW200642682A (en) | A combination of medical drugs to augment the anti-cancer effect of chemotherapy | |
| BRPI0514753A (en) | pharmaceutical dosage forms comprising a low solubility drug and a polymer | |
| BRPI0518855A2 (en) | medicine for hygienic application to the ear |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |